About Sivotec
SIVOTEC Inc., short for Signatures in Vivo Through Technology, is the company behind GENA™, a next‑generation AI-powered genomic analysis platform transforming healthcare through faster, smarter diagnostics.
Our Mission
At SIVOTEC, we’re committed to harnessing artificial intelligence and genomic science to accelerate rare disease diagnostics, empower precision medicine, and make genetic insights accessible to clinicians and researchers worldwide.
What We Do
SIVOTEC is pioneering the future of genomic diagnostics through its flagship platform, GENA. Each solution in the GENA suite is designed to make genetic testing faster, more accurate, and more accessible—helping healthcare providers and laboratories deliver precision medicine at scale.
What We Do
SIVOTEC is pioneering the future of genomic diagnostics through its flagship platform, GENA. Each solution in the GENA suite is designed to make genetic testing faster, more accurate, and more accessible—helping healthcare providers and laboratories deliver precision medicine at scale.
What We Do
SIVOTEC is pioneering the future of genomic diagnostics through its flagship platform, GENA. Each solution in the GENA suite is designed to make genetic testing faster, more accurate, and more accessible—helping healthcare providers and laboratories deliver precision medicine at scale.
What We Do
SIVOTEC is pioneering the future of genomic diagnostics through its flagship platform, GENA. Each solution in the GENA suite is designed to make genetic testing faster, more accurate, and more accessible—helping healthcare providers and laboratories deliver precision medicine at scale.
Our Impact
Since its founding more than nine years ago, GENA™ has empowered 1,600+ geneticists, processed 160,000+ case analyses, and achieved widespread deployment in over 40 countries, helping to deliver precision care faster and more efficiently.
Building The Future
At SIVOTEC, we believe every patient deserves fast, accurate, personalized genetic diagnosis. Through GENA, we’re making that possible, streamlining genomic workflows, empowering clinicians, and delivering smarter care.
Executive Leadership Team
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Pete Martinez serves as Chairman and CEO of SIVOTEC BioInformatics. An international entrepreneur, he has led numerous high impact initiatives in the areas of high technology, business consulting, healthcare, and education. During his 32-year tenure with IBM, he was Vice President of Global Business Services and the Senior Location Executive for IBM South Florida, where he led projects in the areas of advanced research, super-computing and information-based medicine.
Richard Simon is an experienced healthcare executive in the medical community. Richard served at Tenet as Physician Services Regional Director, Mednax Director of Operations, and National Director of Pediatric Cardiology. Richard now serves as COO at Sivotec, focusing on Marketing, Product & Operations.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Luis Pintado is Chief Product Officer and Director at GENA. A serial entrepreneur with a track record of private exits exceeding $60M ARR, he brings 25+ years of experience building and scaling companies in mobile, fintech, and bioinformatics. He previously held leadership roles at Meta, BlackBerry, and Mistral Mobile, and co-founded GENA to accelerate rare disease diagnosis through AI-powered genomic tools. Luis holds a BBA from ITESM and an MBA from MIT Sloan.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Dr. Klaas Wierenga is a board-certified medical geneticist and medical biochemical geneticist at Mayo Clinic in Jacksonville, whose specialty is around clinical care to patients with or suspected to have genetic disorders. His research interests are focused on using information technology for diagnostics and gene discovery.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Niko von Huetz serves as a Director at GENA. A 25-year software entrepreneur and seasoned investment professional, he has held leadership roles at the VC firm Add Partners and private equity firm Saints Capital. Niko has led and managed growth and late-stage investments across SaaS, internet, and infrastructure, with multiple successful exits including to Salesforce, Bloomberg, and Amdocs. He holds a BSc and MSc from Stanford University and an MBA from INSEAD.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Dr. Nick Tsinoremas is Chief Technology Officer at GENA. He is the Vice Provost for Research Computing & Data and Founding Director of the Institute for Data Science & Computing at the University of Miami. With a career spanning informatics, digital health, clinical genomics, and drug discovery, he has held research leadership roles at The Scripps Research Institute and Merck. Nick holds a BA in Chemistry from the University of Athens and a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Daria Salyakina, Ph.D. is Director of Analytics Products at GENA. A published data scientist with deep expertise in pharmacogenetics and genomic medicine, she previously led precision medicine efforts at Nicklaus Children's Health System and served as Principal Investigator at the University of Miami’s Center for Computational Science. Daria has contributed to over 30 scientific publications and brings extensive experience in real-world evidence, bioinformatics, and health economics research.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Christopher Mader has over 20 years of software architecture and design expertise with organizations such as Stanford University, The Institute for Genomic Research, and The Scripps Research Institute, particularly focusing on genomics and bioinformatic applica-tions. He is Director of Software Engineering at University of Miami’s Center for Computational Science.
Board of Directors & Advisory Board
External Board of Directors & Advisory Board
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
DK Singh is a Board Advisor at GENA and a seasoned executive with global leadership experience across procurement, technology, and venture capital. He served as Chief Procurement Officer at Walmart, where he led strategic sourcing and supplier partnerships on a global scale. DK currently advises McKinsey & Company and sits on the boards of Coforge and Cigniti Technologies. He is also an active venture capitalist with Hyde Park Angels, supporting innovation across emerging tech sectors.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Carmen Castillo serves on the Board of Directors at GENA. She is President and CEO of SDI International Corp, a global Hispanic woman-owned procurement and services firm. Carmen is a member of the Council on Foreign Relations, Vice-Chair of IWEC, and former Chair of the United States Hispanic Chamber of Commerce.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Dr. Rachel Burnside is a Scientific Advisor at GENA. A clinical cytogeneticist and industry leader, she brings over 15 years of experience in genomics, diagnostics, and product strategy. She is currently a professor at the University of Florida and previously held leadership roles at Bionano Genomics, Beckman Coulter, and LabCorp. Dr. Burnside’s work bridges research, clinical application, and commercial development in genomic medicine.
Join Us in Building What’s Next
We're constantly evolving. From expanding our AI models to building new platforms, Sivotec is investing in the future of health technology.
Get in Touch
Discover how GENA is shaping the future of healthcare through AI-powered genomics and data analytics. Together, we can unlock the potential of personalized medicine and bring better care to all.